GNPX - ジェンプレックス (Genprex Inc.) ジェンプレックス

 GNPXのチャート


 GNPXの企業情報

symbol GNPx
会社名 Genprex Inc (ジェンプレックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Genprex Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform including its initial product candidate Oncoprex immunogene therapy or Oncoprex. The Company’s Oncoprex is lead product candidate is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer including breast head and neck renal cell (kidney) soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells re-establishes pathways for apoptosis.   ジェンプレックスは米国のバイオ医薬品企業。臨床段階で、同社独自「Oncoprex」免疫療法を含むがん治療における遺伝子治療の開発に従事する。同社プラットフォ―ムは、がんを抑制する遺伝子を管理し、静脈内に投与され腫瘍に取り込まれたがん遺伝子が作るたんぱく質を発現する。同技術に関するテキサス大学がんセンタ―の特許を所有。本社はテキサス州オ―スティン。   Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.
本社所在地 1701 Trinity Street Suite 3.322 Austin TX 78712 USA
代表者氏名 J. Rodney Varner J.ロドニー・バナー
代表者役職名 Chairman of the Board Chief Executive Officer Secretary
電話番号 +1 512-708-0155
設立年月日 39904
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.genprex.com
nasdaq_url https://www.nasdaq.com/symbol/gnpx
adr_tso
EBITDA EBITDA(百万ドル) -8.09860
終値(lastsale) 2
時価総額(marketcap) 30075888
時価総額 時価総額(百万ドル) 26.61716
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 14.61562
当期純利益 当期純利益(百万ドル) -8.13689
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Genprex Inc revenues was not reported. Net loss increased from $1.9M to $6.8M. Higher net loss reflects General and administrative increase from $1.8M to $6.6M (expense) Depreciation increase of 51% to $2K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.51.

 GNPXのテクニカル分析


 GNPXのニュース

   Proactive news headlines including Nextleaf Solutions, Genprex, Ready Set Gold, Sigma Lithium and Esports Entertainment  2021/06/23 18:40:00 Intrado Digital Media
New York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:
   Genprex initiates early-stage REQORSA lung cancer study  2021/06/23 12:44:31 Seeking Alpha
   Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review  2021/06/23 12:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Companys clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Companys
   Is Genprex, Inc. (GNPX) A Good Stock To Buy Now?  2021/06/22 23:08:01 Insider Monkey
   Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX)  2021/05/20 19:56:00 Stock Market Daily
Earnings results for Genprex , Analyst Opinion on Genprex , Earnings and Valuation of (NASDAQ:GNPX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX) appeared first on .
   Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX)  2021/05/20 19:56:00 Stock Market Daily
Earnings results for Genprex , Analyst Opinion on Genprex , Earnings and Valuation of (NASDAQ:GNPX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX) appeared first on .
   Genprex Inc. Shares Close the Week 39.8% Higher - Weekly Wrap  2021/02/05 22:30:00 Kwhen Finance
Genprex Inc. shares closed this week 39.8% higher than it did at the end of last week. The stock is currently up 50.6% year-to-date, up 337.1% over the past 12 months, and up 33.0% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.8%. Trading Activity Shares traded as high as $6.86 and as low as $4.37 this week.Shares closed 0% below its 52-week high and 4e+2% above its 52-week low.Trading volume this week was 110.9% higher than the 10-day average and 169.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 12.4% higher than its 5-day moving average, 42.1% higher than its 20-day moving average, and 67.8% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -27.8% The company's stock price performance over the past 12 months beats the peer average by 143.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genprex Inc. Shares Close the Week 53.5% Higher - Weekly Wrap  2020/12/24 22:30:00 Kwhen Finance
Genprex Inc. shares closed this week 53.5% higher than it did at the end of last week. The stock is currently up 1621.9% year-to-date, up 2005.5% over the past 12 months, and up 17.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $5.72 and as low as $3.50 this week.Shares closed 2e+1% below its 52-week high and 2e+3% above its 52-week low.Trading volume this week was 30.6% higher than the 10-day average and 181.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio is the same as its average peer. The company's performance over the last 1 year beats its average peer by 1738.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genprex Inc. Shares Close the Day 14.9% Lower - Daily Wrap  2020/12/24 22:30:00 Kwhen Finance
Genprex Inc. shares closed today 14.9% lower than it did at the end of yesterday. The stock is currently up 1621.9% year-to-date, up 2005.5% over the past 12 months, and up 17.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.4%. Trading Activity Shares traded as high as $5.72 and as low as $3.50 this week.Shares closed 2e+1% below its 52-week high and 2e+3% above its 52-week low.Trading volume this week was 30.6% higher than the 10-day average and 181.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio is the same as its average peer. The company's performance over the last 1 year beats its average peer by 1738.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   44 Biggest Movers From Yesterday  2021/04/09 09:04:24 Benzinga
Gainers Chemomab Therapeutics Ltd. (NASDAQ: CMMB ) shares jumped 111.5% to close at $55.00 on Thursday. ORBCOMM Inc. (NASDAQ: ORBC ) gained 52.1% to close at $11.51 on Thursday. GI Partners has agreed to acquire Internet of Things (IoT) solutions provider ORBCOMM for $1.1 billion, including net debt. Rice Acquisition Corp. (NYSE: RICE ) climbed 51.7% to settle at $15.32 after the company announced a merger agreement to combine Aria Energy and Archaea Energy into the industry-leading renewable natural gas platform. Vericity, Inc. (NASDAQ: VERY ) shares surged 44.6% to close at $14.55 on Thursday. Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX ) gained 30.4% to settle at $6.00. Virpax Pharmaceuticals recently announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT ) rose 28.9% to settle at $7.49 after the company announced it received an unsolicited non-binding offer to acquires all shares of its common stock for $9 per share.
   Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants  2021/02/09 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
   Genprex Recognizes World Cancer Day  2021/02/04 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
   Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo  2021/01/21 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.
   Genprex to Present at NobleCon17 on January 19  2021/01/14 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェンプレックス GNPX Genprex Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)